Sinobiopharma Announces Improved Q2

Sinobiopharma reported greatly improved financial results for its Q2 (ended November 30, 2009). The company said revenues jumped 120% to $2.1 million and net income was $1.1 million, a $2.1 million increase from the year-earlier quarter. Sinobiopharma attributed the rise in revenue to continuing marketing of its major revenue driver, the muscle relaxant KuTai (cisatracurium besylate). More details.. Stock Symbol: (OTCBB: SNBP)